C-Reactive Protein Reassessed

New England Journal of Medicine

Volumn 350, Issue 14, 2004, Pages 1450-1452

  Tall, Alan R ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN;

BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; DISEASE MARKER; EDITORIAL; HUMAN; ISCHEMIC HEART DISEASE; MULTIVARIATE ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BINDING; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; THROMBOSIS;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY DISEASE; HUMANS; INFLAMMATION; RISK;

EID: 1842483357     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe048020     Document Type: Editorial

References (12)

1. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387-97.
2. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-65.
3. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
4. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol 1996;144:537-47.
5. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9. [Erratum, N Engl J Med 1997;337:356.]
6. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9. [Erratum, N Engl J Med 1997;337:356.]
7. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003;111:1805-12. [Erratum, J Clin Invest 2003;112:299.]
8. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003;111:1805-12. [Erratum, J Clin Invest 2003;112:299.]
9. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-808.
10. Chang MK, Binder CJ, Torzewski M, Witztum JL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci U S A 2002;99:13043-8.
11. Hirschfield GM, Gallimore R, Gilbertson JA, Benson M, Pepys MB. Systemic inflammation and atherogenesis in apoE knockout mice expressing transgenic human C-reactive protein. Circulation 2003;108:Suppl IV:IV-41. abstract.
12. Paul A, Ko KW, Li L, et al. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004;109:647-55.